| Identification | Back Directory | [Name]
Omburtamab | [CAS]
1895083-75-6 | [Synonyms]
Omburtamab
Omburtamab (anti-CD276)
Research Grade Omburtamab
Research Grade Omburtamab(DHJ04002) |
| Hazard Information | Back Directory | [Uses]
Omburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research[1][2]. | [References]
[1] Liu J, et al. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol Oncol. 2021 Jan 29;14(1):21. DOI:10.1186/s13045-020-01024-8
[2] Kaplon H, et al. Antibodies to watch in 2020. MAbs. 2020 Jan-Dec;12(1):1703531. DOI:10.1080/19420862.2019.1703531 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|